Kareemah Hammond
Psychiatric/Mental Health · Newark, DENPI 1588192421
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 142 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Johnson & Johnson at 32.0% of the total.
Across 142 payments — averaging $29.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$574
- Otsuka America Pharmaceutical, Inc.$359
- Novo Nordisk$322
- Lundbeck LLC$276
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$232
- plus $1K from 10 others
What the payments were for
- Food & beverage$4,13998%
- Education$752%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 44 | $1,348 |
| AbbVie | 21 | $574 |
| Otsuka America Pharmaceutical, Inc. | 12 | $359 |
| Novo Nordisk | 4 | $322 |
| Lundbeck LLC | 14 | $276 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 12 | $232 |
| Alkermes, Inc. | 7 | $203 |
| E.r. Squibb & Sons, L.L.C. | 8 | $175 |
| Axsome Therapeutics, Inc. | 3 | $141 |
| Vanda Pharmaceuticals Inc. | 6 | $126 |
| Lilly USA, LLC | 2 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $92 |
| Gilead | 1 | $89 |
| Qiagen, LLC | 1 | $64 |
| Braeburn Inc. | 1 | $64 |
| Neurocrine Biosciences, Inc. | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$338
- Ozempic$246
- VRAYLAR$218
- REXULTI$108
- MOUNJARO$100
How this compares
$4,214 in reported general payments places this provider in the 85th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 58 | $86,159 |
| Invega SustennaPaliperidone Palmitate | 14 | $33,453 |
| Aripiprazole | 84 | $21,607 |
| Divalproex Sodium | 33 | $7,016 |
| Clomipramine Hcl | 23 | $6,094 |
| Divalproex Sodium ErDivalproex Sodium | 74 | $5,080 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,991 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 28 | $4,696 |
| Chlorpromazine Hcl | 18 | $4,240 |
| Ziprasidone Hcl | 14 | $2,868 |
| Atomoxetine Hcl | 13 | $2,564 |
| Quetiapine Fumarate | 140 | $2,479 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 22 | $1,620 |
| Guanfacine Hcl ErGuanfacine Hcl | 26 | $1,410 |
| Fluvoxamine Maleate | 28 | $1,375 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $574 | $86,15958 claims |
| Johnson & JohnsonInvega Sustenna | $1,348 | $33,45314 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $92 | $4,99113 claims |
| Lilly USA, LLCOlanzapine | $119 | $33732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 177 psychiatric/mental health providers in Delaware.
Other psychiatric/mental health in Newark
- Kameka HartNewark$10K
- Bradley WhyNewark$6K
- Ema SohnaNewark$5K
- Tiffany DysonNewark$3K
- Bernadette MomohNewark$3K
- Stefanie FerraroNewark$2K
- Catherine LukoNewark$2K
- Ronald TyreeWilmington$59K
- Ericka Taylor-DanielDover$39K
- Cindy CunninghamDover$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.